Valuation: Sanofi

Market Cap 105B 116B 97.07B 87.58B 165B 10,920B 171B 1,166B 462B 5,833B 435B 425B 18,516B P/E 2026 *
13.9x
P/E 2027 * 11.7x
Enterprise Value 116B 128B 107B 96.87B 183B 12,077B 189B 1,290B 511B 6,452B 481B 470B 20,479B EV / Sales 2026 *
2.4x
EV / Sales 2027 * 2.16x
Free-Float
88.8%
Yield 2026 *
4.86%
Yield 2027 * 5.13%
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer - 2026-08-31
Director TitleAgeSince
Director/Board Member 61 2019-04-29
Director/Board Member 56 2020-04-27
Director/Board Member 65 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+6.12%-1.27% - - 116B
+1.26%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
-0.44%+3.69%+41.45%+70.04% 386B
+0.55%+0.70%+59.02%+45.79% 364B
-0.12%+0.74%+28.39%+60.32% 302B
+0.37%+0.37%+3.33%+38.57% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.85%+2.08%+35.39%+84.55% 477B
Weighted average by Cap. +0.68%+3.26%+37.70%+99.28%

Financials

2026 *2027 *
Net sales 48.43B 53.45B 44.8B 40.42B 76.17B 5,039B 78.86B 538B 213B 2,692B 201B 196B 8,545B 51.68B 57.02B 47.8B 43.12B 81.27B 5,377B 84.13B 574B 228B 2,872B 214B 209B 9,117B
Net income 7.64B 8.43B 7.07B 6.38B 12.02B 795B 12.44B 84.93B 33.67B 425B 31.65B 30.98B 1,348B 9.21B 10.16B 8.52B 7.68B 14.48B 958B 14.99B 102B 40.57B 512B 38.13B 37.32B 1,625B
Net Debt 11.13B 12.28B 10.29B 9.28B 17.5B 1,158B 18.11B 124B 49.01B 618B 46.07B 45.09B 1,963B 6.83B 7.53B 6.31B 5.7B 10.73B 710B 11.11B 75.83B 30.07B 379B 28.26B 27.66B 1,204B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Sanofi